GSK receives good news on ViiV's Trimeq HIV treatment
27th Jun 2014 14:33
GlaxoSmithKline (GSK) shares moved higher on Friday after ViiV Healthcare, the HIV-focused business jointly owned with Pfizer, took a step forward in the marketing authorisation process for its Triumeq treatment. Based on two studies, the Committee for Medicinal Products for Human Use of the Europe
Read moreSector movers: Shire soars as M&A fever boosts pharma, health stocks
20th Jun 2014 13:56
News that Shire has rejected a £27bn approach by AbbVie sent shares in the pharmaceutical and healthcare equipment sectors higher on Friday as yet more M&A continued to give sentiment a boost. "A bit of M&A excitement has been just the ticket to enliven trading on what may otherwise have been somet
Read moreLondon midday: Stocks rise as M&A boosts Shire, TSB jumps on debut
20th Jun 2014 11:39
- FTSE 100 at one-week high - Shire jumps after rejecting £27bn AbbVie proposal - TSB rises strongly after IPO - Iran still in the spotlight as Obama sends advisers techMARK 2,849.46 +1.26% FTSE 100 6,827.82 +0.29% FTSE 250 15,761.52 +0.49% UK stocks were making gains on Friday as yet more M&A fev
Read moreMonday broker round-up UPDATE
16th Jun 2014 09:51
Allocate Software: N+1 Singer upgrades to buy with a target price of 133p. Croda International: Numis cuts target price from 2575p to 2554p and maintains its hold recommendation. Diamondcorp: Northland Capital shifts target price from 9.9p to 11p and keeps a buy recommendation. Fenner: Credit Su
Read moreGlaxoSmithKline unveils positive data from COPD studies
11th Jun 2014 12:44
GlaxoSmithKline (GSK) and partner Theravance on Wednesday unveiled positive data from two of their studies into the efficacy and safety of their Incruse Ellipta product, which is being developed for the treatment of chronic obstructive pulmonary disease (COPD). The results are from two phase three
Read moreGSK signs deal with UK biotech firm to develop cancer drugs
2nd Jun 2014 12:08
GlaxoSmithKline (GSK) has signed a deal with a UK biotech company to develop new cancer drugs. GSK will pay Adaptimmune as much as $350m over the next seven years. Adaptimmune and GSK will work together to develop cell-based cancer therapies that involve re-engineering patients' white blood cells
Read moreSunday share tips: Glaxo, Genel, Treatt
1st Jun 2014 11:30
Buy shares of Genel Energy, Danny Fortson urged in the Sunday Times's Inside the City column. The oil explorer sold a tanker of crude from Kurdistan last month for the market rate of more than $100 a barrel. Previous sales have been below the Brent crude price because of lack of infrastructure and p
Read moreLondon midday: Miners pull UK markets lower, but Smith & Nephew rises
30th May 2014 11:34
- Mining stocks lower on iron ore, China concerns - Fenner issues profit warning - M&A continues to boost Smith & Nephew techMARK 2,820.23 +0.39% FTSE 100 6,860.62 -0.16% FTSE 250 16,039.31 +0.53% Weakness in the mining sector dragged the UK stock market from a two-week high on Friday, despite M&A
Read moreLondon pre-open: Flat start ahead of consumer confidence, German retail data
30th May 2014 07:28
A flat start is expected for London-listed stocks this morning ahead of today's UK consumer confidence report and German retail data. City sources predict the FTSE 100 will open almost unchanged from yesterday's close of 6,871.29. According to forecasts, the GfK's consumer sentiment index is exp
Read moreGlaxoSmithKline gauges buyer interest for mature drug portfolio
30th May 2014 06:44
GlaxoSmithKline (GSK) is rumoured to have approached a number of private equity firms to gauge the interest for a range of its older drugs as it attempts to refresh its portfolio. According to various reports, the pharmaceutical group has contacted companies including Advent International, Blacksto
Read moreLondon close: Investors tread carefully ahead of record highs
28th May 2014 17:18
- Eurozone money supply weak, German unemployment rises - Markets cautious after recent highs - LSE leads financials higher - GSK to be investigated by UK fraud body techMARK 2,799.81 +0.48% FTSE 100 6,851.22 +0.09% FTSE 250 15,935.43 +0.58% UK stocks ended slightly higher after trading in a narr
Read moreSector movers: M&A continues to lift healthcare stocks as Smith & Nephew jumps
28th May 2014 15:14
Healthcare stocks were at the top of the pile on Wednesday on the back of continued M&A activity in the sector, with UK-listed medical device maker Smith & Nephew in focus on reports of bid interest from overseas. The Financial Times reported today that US group Stryker had hired banks and was work
Read moreFTSE 100 movers: Royal Mail slides on broker rating cut
28th May 2014 14:58
Cantor Fitzgerald reiterated its 'sell' rating on Royal Mail, and cut its target price from 500p to 480p, pushing the stock into the bottom spot. Engineering group Weir fell after announcing it has dropped its pursuit to merge with Metso after continued rejections from the board of the Finnish riva
Read moreLondon midday: Stocks rangebound as investors turn cautious
28th May 2014 11:38
- Eurozone data comes in mixed, German unemployment weak - Markets cautious after recent highs - RBS, LSE lead financials high - GSK to be investigated by UK fraud body techMARK 2,788.03 +0.06% FTSE 100 6,849.21 +0.06% FTSE 250 15,890.88 +0.30% UK stocks were trading in a narrow range on Wednesday
Read moreLondon open: UK markets flat as Glaxo falls
28th May 2014 08:37
- European stocks retreat from six-year highs - Economic data in focus - GSK to be investigated by UK fraud body - Weir drops pursuit of Metso techMARK 2,784.94 -0.05% FTSE 100 6,838.75 -0.09% FTSE 250 15,885.65 +0.26% UK equities opened more or less flat on Wednesday as markets showed caution aft
Read more